Award
National Institute on Drug Abuse 1DP2DA060600-01
Taking Our Shot: Extended-Release Naltrexone as Opioid Overdose Pre-Exposure Prophylaxis (PrEP) in People Using Stimulants Living With or At Risk of HIV
Recipient
Not specified
Award Amount
$2,460,000.00
Ceiling
$2,460,000.00
Awarded
June 10, 2024
Identifier
1DP2DA060600-01
A randomized controlled trial funded by NIDA to test extended-release naltrexone as a preventive treatment for opioid overdose in stimulant users at risk of HIV, focusing on feasibility and effectiveness.
Description
This project proposes a randomized controlled trial to evaluate the effectiveness of extended-release naltrexone as a pre-exposure prophylaxis (PrEP) for opioid overdose among individuals using stimulants and at risk of HIV. The study aims to assess feasibility, acceptability, and preliminary effectiveness, as well as to understand the epidemiology of opioid exposure in this population.